Who
Jill C. Milne
Director
Company insider
Files Form 4 as: Director, BioCryst Pharmaceuticals; CEO and President, Astria Therapeutics.
In numbers
- Trades disclosed
- 40
- Buys
- 0
- Sells
- 0
- Bought
- $0
- Sold
- $0
- Companies
- 2
- Companies where not an officer
- 1
- First trade
- 30 Jun 2015
- Last trade
- 31 Aug 2026
- Last filed
- 2 Sep 2026
Companies traded
Activity over time
Not enough dated trades to draw.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 31 Aug 2026filed 2 Sep 2026 | BCRX BioCryst PharmaceuticalsBiotechnology | SEC FORM 4 Code A | $12K1,288 at $9.70 | filing |
| 31 Aug 2026filed 2 Sep 2026 | BCRX BioCryst PharmaceuticalsBiotechnology | SEC FORM 4 Code A | $12K1,288 at $9.70 | filing |
| 11 Jun 2026filed 15 Jun 2026 | BCRX BioCryst PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —15,294 at $0.00 | filing |
| 11 Jun 2026filed 15 Jun 2026 | BCRX BioCryst Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —33,540 at $0.00 | filing |
| 11 Jun 2026filed 15 Jun 2026 | BCRX BioCryst Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —33,540 at $0.00 | filing |
| 11 Jun 2026filed 15 Jun 2026 | BCRX BioCryst PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —15,294 at $0.00 | filing |
| 29 May 2026filed 2 Jun 2026 | BCRX BioCryst PharmaceuticalsBiotechnology | SEC FORM 4 Code A | $11K1,262 at $8.91 | filing |
| 29 May 2026filed 2 Jun 2026 | BCRX BioCryst PharmaceuticalsBiotechnology | SEC FORM 4 Code A | $11K1,262 at $8.91 | filing |
| 27 Feb 2026filed 3 Mar 2026 | BCRX BioCryst PharmaceuticalsBiotechnology | SEC FORM 4 Code A | $4,620528 at $8.75 | filing |
| 27 Feb 2026filed 3 Mar 2026 | BCRX BioCryst PharmaceuticalsBiotechnology | SEC FORM 4 Code A | $4,620528 at $8.75 | filing |
| 23 Jan 2026filed 27 Jan 2026 | BCRX BioCryst PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —2,582 | filing |
| 23 Jan 2026filed 27 Jan 2026 | BCRX BioCryst PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —12,272 at $0.00 | filing |
| 23 Jan 2026filed 27 Jan 2026 | BCRX BioCryst Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —26,684 at $0.00 | filing |
| 23 Jan 2026filed 27 Jan 2026 | BCRX BioCryst Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —26,684 at $0.00 | filing |
| 23 Jan 2026filed 27 Jan 2026 | BCRX BioCryst PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —2,582 | filing |
| 23 Jan 2026filed 27 Jan 2026 | BCRX BioCryst PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —12,272 at $0.00 | filing |
| 23 Jan 2026filed 23 Jan 2026 | Astria TherapeuticsBiotechnology | SEC FORM 4 Code D | —4,377 | filing |
| 23 Jan 2026filed 23 Jan 2026 | Astria Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —195,000 | filing |
| 23 Jan 2026filed 23 Jan 2026 | Astria Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —761,000 | filing |
| 23 Jan 2026filed 23 Jan 2026 | Astria Therapeuticsoption or derivative | SEC FORM 4 Code D | —195,000 | filing |
News
No headline names them, or the companies they trade most, lately.
Sectors
No trade we could place in a sector.